Table 2.

Characteristics of patients according to IV bDMARD. Values are % unless otherwise specified.

Patients, n (%)129 (22.9)213 (37.9)221 (39.2)
Total time taking drug, mos, mean (SD)27.4 (21.3)41.7 (33.3)31.1 (22.3)0.03
  Rheumatoid arthritis98.431.992.3
  Axial spondyloarthritis51.7
  Psoriatic arthritis13.6
Concomitant sDMARD**
  Methotrexate59.644.666.8< 0.001
  Leflunomide12.42.345.4< 0.001
  • * p values are supplemented as appropriate.

  • ** At baseline. IV: intravenous; DMARD: disease-modifying antirheumatic drugs; bDMARD: biological DMARD; JIA: juvenile idiopathic arthritis; sDMARD: synthetic DMARD.